Grantee Name: Prof. Bindra Ranjit
Organization: Yale University
Country: USA
Project Name:
Phase 2 Study of the PARP Inhibitor Olaparib in IDH1/2-mutant solid tumors
Funding Year:
2018
Project period: 3 years
Phase 2 Study of the PARP Inhibitor Olaparib in IDH1/2-mutant solid tumors
To conduct a comprehensive series of correlative studies in tumor biopsies to identify which patients with IDH1/2 tumor mutations respond best to the DNA repair inhibitor, Olaparib.
Lay Abstract
Our collaborative research group at Yale recently discovered that tumors with mutations in two key metabolism-related genes, IDH1 and IDH2, induce exquisite sensitivity to DNA repair inhibitors. In particular, the DNA repair inhibitor, olaparib, was recently FDA-approved for the treatment of ovarian cancers with gene mutations that induce a similar sensitivity. In this proposal, we will perform a clinical trial which will test whether olaparib is effective against tumors with IDH1 and IDH2 mutations. We will perform a comprehensive series of correlative studies in tumor biopsies, in order to identify which patients respond best. This study represents a true bench-to-bedside endeavor, and it leverages the best Yale science with the goal of improving the lives of cancer patients.
We care about your data, and we use cookies only to improve your experience. Read our Privacy Policy